Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedtronicMDT -0.08%74 EV-to-EBIT is 18.88 as of Aug. 06, 2026, which is 16% below its 10-year median of 22.61. GuruFocus rates MDT with a GF Score™ of 74/100 and a GF Value™ of $100.19 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 469 Medical Devices & Instruments companies, Medtronic ranks worse than 50.11% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medtronic's Enterprise Value for the quarter that ended in Apr. 2026 was $123,006 Mil.
Medtronic's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6,851 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medtronic EV-to-EBIT Related Terms
Medtronic EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Medtronic's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medtronic's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medtronic EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medtronic's EV-to-EBIT falls into.
Medtronic's current Enterprise Value is $129,331 Mil.
Medtronic's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6,851 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medtronic (MDT) has a EV-to-EBIT of 18.88 as of Aug. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medtronic and its competitors. This is 16% below median its historical median of 22.61. Over the past decade, Medtronic's EV-to-EBIT has ranged from 16.70 to 55.68. According to the industry distribution chart, Medtronic ranks #235 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 50.1%.
Is Medtronic's EV-to-EBIT too high?
Medtronic's current EV-to-EBIT of 18.88 is 16% below median its 10-year median of 22.61. Over the past 10 years, this metric has ranged from a low of 16.70 to a high of 55.68. The Medical Devices & Instruments industry median EV-to-EBIT is 18.89. Medtronic's value of 18.88 is 0.1% below this industry median. Based on the distribution chart, Medtronic ranks #235 out of 469 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medtronic has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's EV-to-EBIT compare to SYK and BSX?
According to the Medical Devices & Instruments industry distribution chart, Medtronic ranks #235 out of 469 companies for EV-to-EBIT. This places Medtronic in the lower half of its industry. The industry median EV-to-EBIT is 18.89. Medtronic's value of 18.88 is 0.1% below this benchmark. Historically, Medtronic's own EV-to-EBIT has ranged from 16.70 to 55.68 over the past decade. While the company's 10-year median is 22.61 vs. the industry median of 18.89, Medtronic has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.89, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medtronic's current EV-to-EBIT of 18.88 is 0.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medtronic and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medtronic's current EV-to-EBIT is 18.88, which is 16% below median its own 10-year median of 22.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (MDT) is currently considered Modestly Undervalued. The stock's GF Value™ is $100.19, compared to a current price of $85.92 — trading 14.2% below its estimated fair value. The current EV-to-EBIT is 18.88, which is 16% below median its 10-year median of 22.61 and 0.1% below the Medical Devices & Instruments industry median of 18.89. Medtronic's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Medtronic (MDT), the current EV-to-EBIT is 18.88 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medtronic (MDT) Overvalued in 2026?
Based on GuruFocus' analysis, Medtronic stock appears to be undervalued.
The current stock price of $85.92 is trading 14.2% below its estimated GF Value™ of $100.19.
GuruFocus considers Medtronic to be Modestly Undervalued.
Key valuation signals for MDT:
EV-to-EBIT: 18.88 (16% below median its 10-year median of 22.61)
GF Value™: $100.19 vs. price of $85.92 (14.2% below fair value)
Industry Position: 0.1% below the Medical Devices & Instruments median (#235 of 469)
No single metric tells the full story. See the MDT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
74GF Score
Get the complete analysis for MDT
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDT has been successfully added to your 
